2 No-Brainer Dividend Stocks to Buy With $100 in November

The article highlights Coca-Cola (KO) and Pfizer (PFE) as dividend-oriented investment opportunities under $100 per share. Coca-Cola is presented as a stable, long-term income play, boasting 63 consecutive years of dividend increases, strong brand power, and resilient demand. Pfizer, despite recent revenue and earnings declines, is positioned as an undervalued prospect for patient investors, driven by significant cost-cutting initiatives projected to save $7.2 billion by 2027, pipeline expansion, and an attractive ~7% forward dividend yield, even as it navigates an upcoming patent cliff.

Analysis

Coca-Cola (KO) presents a compelling case for income-oriented investors, evidenced by its remarkable 63 consecutive years of dividend increases, a testament to its robust brand power and resilient demand across economic cycles. The company's strategic ability to launch new products like Coca-Cola Spiced and Simply Pop, alongside its extensive portfolio and pricing power, underpins consistent revenue and earnings growth, even as shares trade under $69. This operational strength allows KO to maintain its dividend growth trajectory and market dominance.

Conversely, Pfizer (PFE) faces near-term headwinds, with Q3 revenue declining 6% year-over-year to $16.7 billion and adjusted EPS falling 18% to $0.87. Despite this, the pharmaceutical giant has reaffirmed its 2025 revenue guidance and raised earnings guidance, driven by better-than-expected cost-cutting initiatives projected to yield $7.2 billion in net savings by 2027. A recent deal avoiding tariffs for three years further supports operating margins.

PFE's long-term outlook hinges on its expanded pipeline through acquisitions and new product approvals, though results are not immediate and the company faces an upcoming patent cliff for Eliquis. Trading at approximately $25 per share with a forward P/E of 8.7, significantly below the healthcare industry average of 17.1, and offering a ~7% forward dividend yield, Pfizer appears undervalued for patient investors willing to navigate its transitional phase.

Key Decisions for Investors

• Consider Coca-Cola (KO) as a stable, long-term core holding for defensive income portfolios, given its consistent dividend growth and strong brand resilience.
• Evaluate Pfizer (PFE) as a contrarian value opportunity for patient investors, weighing its attractive valuation and high dividend yield against near-term revenue pressures and the Eliquis patent cliff.
• Monitor Pfizer's execution on its $7.2 billion cost-saving initiatives and the successful integration and commercialization of its expanded product pipeline to assess its turnaround potential.